Fulgent Genetics, Inc. (FLGT): Price and Financial Metrics

Fulgent Genetics, Inc. (FLGT): $21.81

0.12 (+0.55%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

FLGT Price/Volume Stats

Current price $21.81 52-week high $44.09
Prev. close $21.69 52-week low $21.23
Day low $21.70 Volume 78,877
Day high $22.16 Avg. volume 210,808
50-day MA $24.10 Dividend yield N/A
200-day MA $29.18 Market Cap 649.61M

FLGT Stock Price Chart Interactive Chart >

FLGT POWR Grades

  • Quality is the dimension where FLGT ranks best; there it ranks ahead of 69.8% of US stocks.
  • FLGT's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
  • FLGT's current lowest rank is in the Stability metric (where it is better than 20.75% of US stocks).

FLGT Stock Summary

  • The ratio of debt to operating expenses for FULGENT GENETICS INC is higher than it is for about just 5.81% of US stocks.
  • With a year-over-year growth in debt of -85.89%, FULGENT GENETICS INC's debt growth rate surpasses merely 1.69% of about US stocks.
  • Revenue growth over the past 12 months for FULGENT GENETICS INC comes in at -64.33%, a number that bests merely 3.35% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to FLGT, based on their financial statements, market capitalization, and price volatility, are ONTF, CSTL, UDMY, SILK, and HIPO.
  • FLGT's SEC filings can be seen here. And to visit FULGENT GENETICS INC's official web site, go to www.fulgentgenetics.com.

FLGT Valuation Summary

  • In comparison to the median Healthcare stock, FLGT's price/sales ratio is 28.57% lower, now standing at 3.
  • Over the past 88 months, FLGT's price/sales ratio has gone down 13.3.

Below are key valuation metrics over time for FLGT.

Stock Date P/S P/B P/E EV/EBIT
FLGT 2023-12-29 3.0 0.7 -13.5 -12.7
FLGT 2023-12-28 3.1 0.7 -13.9 -13.2
FLGT 2023-12-27 3.1 0.7 -14.1 -13.3
FLGT 2023-12-26 3.1 0.7 -14.1 -13.4
FLGT 2023-12-22 3.1 0.7 -14.1 -13.4
FLGT 2023-12-21 3.1 0.7 -13.9 -13.2

FLGT Growth Metrics

    Its 3 year price growth rate is now at 880.18%.
  • Its 2 year net income to common stockholders growth rate is now at 100459.91%.
  • The year over year price growth rate now stands at -27.12%.
FLGT's revenue has moved up $784,659,000 over the prior 70 months.

The table below shows FLGT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 802.935 297.399 271.574
2022-06-30 925.148 428.824 392.377
2022-03-31 953.423 493.809 460.652
2021-12-31 992.584 538.577 507.364
2021-09-30 1,035.891 595.747 569.332
2021-06-30 909.739 452.961 493.448

FLGT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FLGT has a Quality Grade of C, ranking ahead of 74.39% of graded US stocks.
  • FLGT's asset turnover comes in at 1.214 -- ranking 12th of 81 Healthcare stocks.
  • MGLN, UHS, and ADUS are the stocks whose asset turnover ratios are most correlated with FLGT.

The table below shows FLGT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.214 0.793 1.237
2021-03-31 1.514 0.793 1.595
2020-12-31 1.489 0.787 1.426
2020-09-30 1.037 0.692 0.646
2020-06-30 0.522 0.559 0.028
2020-03-31 0.472 0.565 -0.007

FLGT Price Target

For more insight on analysts targets of FLGT, see our FLGT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $103.00 Average Broker Recommendation 1.5 (Moderate Buy)

Fulgent Genetics, Inc. (FLGT) Company Bio


Fulgent Genetics, Inc., a technology company, focuses on providing genetic testing services to physicians with clinically actionable diagnostic information. It intends to provide tests to hospitals and medical institutions. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is based in Temple City, California.


FLGT Latest News Stream


Event/Time News Detail
Loading, please wait...

FLGT Latest Social Stream


Loading social stream, please wait...

View Full FLGT Social Stream

Latest FLGT News From Around the Web

Below are the latest news stories about FULGENT GENETICS INC that investors may wish to consider to help them evaluate FLGT as an investment opportunity.

The 3 Best Digital Health Stocks for Personalized Medicine

Digital health stocks are becoming increasingly relelvant as more and more people seek greater control over their health.

Alex Sirois on InvestorPlace | November 25, 2023

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

EL MONTE, Calif., November 14, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

Yahoo | November 14, 2023

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Hello, and welcome to the Fulgent Genetics Q3 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to turn the call […]

Yahoo | November 5, 2023

Q3 2023 Fulgent Genetics Inc Earnings Call

Q3 2023 Fulgent Genetics Inc Earnings Call

Yahoo | November 4, 2023

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

EL MONTE, Calif., November 03, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

Yahoo | November 3, 2023

Read More 'FLGT' Stories Here

FLGT Price Returns

1-mo -14.40%
3-mo -24.56%
6-mo -18.44%
1-year -26.81%
3-year -77.79%
5-year 266.55%
YTD -24.56%
2023 -2.92%
2022 -70.39%
2021 93.07%
2020 303.88%
2019 306.94%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!